[go: up one dir, main page]

WO1992019594A1 - Pyrrolidinones - Google Patents

Pyrrolidinones Download PDF

Info

Publication number
WO1992019594A1
WO1992019594A1 PCT/US1992/003613 US9203613W WO9219594A1 WO 1992019594 A1 WO1992019594 A1 WO 1992019594A1 US 9203613 W US9203613 W US 9203613W WO 9219594 A1 WO9219594 A1 WO 9219594A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
cyclopentyloxy
methoxyphenyl
substituted
pyrrolidinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/003613
Other languages
English (en)
Inventor
Paul Elliot Bender
Siegfried Benjamin Christensen, Iv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to JP4511481A priority Critical patent/JPH06507405A/ja
Publication of WO1992019594A1 publication Critical patent/WO1992019594A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to novel pyrrolidinones, pharmaceutical compositions containing these compounds and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).
  • TNF Tumor Necrosis Factor
  • Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.
  • cromoglycate are inadequate to control the disease; none of them modify all three phases of asthma and nearly all are saddled with limiting side effects. Most importantly, none of the agents, with the possible exception of steroids, alter the course of progression of chronic asthma.
  • Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones
  • Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the
  • PDEs cyclic nucleotide phosphodiesterases
  • PDE cyclic nucleotide phosphodiesterase
  • Isozymes Potential Targets for Novel Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd. (1989). Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils. Moreover, the beneficial effects of PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo.
  • PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated. Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
  • the compounds of this invention also inhibit production of Tumor Necrosis Factor (TNF), a serum
  • TNF production is implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sacroidosis, bone resorption diseases, reperfusion injury, graft vs.
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • AIDS cachexia secondary to acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis or pyresis.
  • TNF has been implicated in various roles with the human acquired immune deficiency syndrome (AIDS) .
  • AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HIV).
  • HIV Human Immunodeficiency Virus
  • T lymphocytes implicated in the infection of T lymphocytes with HIV by playing a role in maintaining T lymphocyte activation. Furthermore, once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be
  • TNF is also associated with yeast and fungal infections. Specifically Candida Albicans has been shown to induce TNF production in vitro in human
  • This invention comprises benzyl pyrrolidinones represented by Formula (I), and pharmaceutical
  • compositions containing these compounds are provided.
  • This invention further constitutes a method of inhibiting phosphodiesterase IV in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of
  • Phosphodiesterase IV inhibitors are useful in the treatment of a variety of allergic and
  • inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal
  • PDE IV inhibitors are useful in the treatment of
  • This invention further constitutes a method of inhibiting the production of TNF in an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of formula (I).
  • This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HIV), AIDS Related Complex (ARC) or any other disease state associated with an HIV infection, which comprises administering to such a human an effective TNF inhibiting amount of a compound of Formula (I).
  • HIV human immunodeficiency virus
  • ARC AIDS Related Complex
  • the present invention also provides a method of preventing a TNF mediated disease state in an animal in need thereof, including humans, by prophylactically administering an effective amount of a compound of
  • the compounds of the present invention are also useful in the treatment of additional viral infections
  • viruses contemplated for treatment herein are those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (I).
  • viruses include, but are not limited to; HIV-1, HIV-2 and HIV-3,
  • CMV Cytomegalovirus
  • Influenza Influenza
  • adenovirus adenovirus
  • Herpes group of viruses such as. Herpes Zoster and Herpes Simplex.
  • the compounds of Formula I are also useful in the treatment of yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • a preferred disease state for treatment is fungal meningitis.
  • the compounds of the Formula (I) may be administered in conjunction with other drugs of choice, either simultaneously or in a consecutive manner, for systemic yeast and fungal infections.
  • Drugs of choice for fungal infections include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the
  • Amphotericins in particular Amphotericin B and
  • the preferred organism for treatment is the Candida organism.
  • the compounds of the Formula (I) may be co-administered in a similar manner with anti-viral or anti-bacterial agents.
  • the compounds of the Formula (I) may also be used for inhibiting and/or reducing the toxicity of an anti-fungal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of the Formula (I) to a mammal in need of such treatment.
  • a compound of the Formula (I) is
  • R 1 is C 1-12 alkyl unsubstituted or substituted by 1 or more halogens, C 3-6 cyclic alkyl unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group; C 4-6 cycloalkyl containing one or two unsaturated bonds;
  • X 1 is 0 or S
  • X 2 is 0 or NR 14 ;
  • X 3 is hydrogen or X
  • X is YR 2 , halogen, nitro, NR 14 R 14 , or formamide; Y is 0 or S(O)m;
  • R 2 is -CH 3 or -CH 2 CH 3 , each may be
  • R 3 is hydrogen, halogen, CN, C 1-4 alkyl, halo-substituted C 1-4 alkyl, cyclopropyl unsubstituted or substituted by R 9 , OR 5 , -CH 2 OR 5 , -NR 5 R 16 ,
  • R 3' is hydrogen, halogen, C 1-4 alkyl, halosubstituted C 1-4 alkyl, cyclopropyl unsubstituted or
  • n is an integer from 0 to 2;
  • n is an integer from 1 to 4.
  • q is an integer from 0 to 1;
  • r is an integer from 1 to 2;
  • s is an integer from 2 to 4.
  • x is an integer from 2 to 6;
  • y is an integer from 1 to 6;
  • z is an integer from 0 to 6;
  • R 5 and R 16 may together with the nitrogen form a 5 to 7 membered ring optionally
  • R 5 is independently hydrogen or C 1-4 alkyl, unsubstituted or substituted by one to three fluorines;
  • R 7 is OR 5 , -NR 5 R 16 , or R 12 ;
  • R 8 is hydrogen, C(O)R 7 , (2-, 4- or 5- imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5- triazolyl-[l,2,3]), (3- or 5-triazolyl[1,2,4]), (5- tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5- isoxazolyl), (3- or 5-oxadiazolyl[1,2,4]), (2- oxadiazolyl[l,3,4]), (2-thiadiazolyl[l, 3,4]), (2- ,4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl),
  • R 9 is hydrogen, F or R 12 .
  • R 10 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyC 1-3 alkyl, halo
  • cycloalkyl and heterocyclic moieties may be
  • R 11 is 2-tetrahydropyran or 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group;
  • R 12 is C 1-4 alkyl unsubstituted or substituted by one to three fluorines
  • R 14 is independently hydrogen or a
  • R 15 is C 1-4 alkyl unsubstituted or substituted by one or more halogens; -C(O)C 1-4 alkyl, unsubstituted or substituted by one or more halogens; oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, or pyrrolyl, and each of the heterocyclics may be unsubstituted or substituted by one or two C 1-2 alkyl groups;
  • R 16 is OR 5 or R 5 ;
  • Z is O, -NR 12 , -NOR 5 , NCN, -C(-CN) 2 ,
  • m is 2 when R 10 is OH in (CR 14 R 14 )n-C(O)O- (CR 14 R 14 ) m -R 10 , (CR 14 R 14 ) n - (C(O)NR 14 ) - (CR 14 R 14 ) m -R 10, or C(R 14 R 14 ) s O(CR 14 R 14 ) m R 10 and further provided that at least one of the R 4 or R 14 groups on (a) or (b) is not hydrogen when q is O, R 3 , R 3' , R 8 and X 3 are H; X is OR 2 , X 2 is O and X, is O or S.
  • All defined alkyl groups can be straight or branched.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are contemplated to be within the scope of the present invention.
  • the term "halogen" is used to mean chloro, fluoro, bromo or iodo. Alkyl groups may be substituted by one or more halogens up to being
  • cycloalkyl as used herein is meant to include groups of 3-6 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl or
  • aryl or “aralkyl”, unless specified otherwise, as used herein is meant an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl or naphthyl.
  • aryl is monocyclic, i.e., phenyl.
  • C 7-11 polycycloalkyl examples include bicyclo [2.2.1]-heptyl, bicyclo [2.2.2] octyl,
  • rings when R 5 and R 16 in the moiety -NR 5 R 16 together with the nitrogen to which they are attached form a 5- to 7 membered ring optionally containing at least one additional heteroatom selected from O/N/ and S include, but are not limited to
  • the invention further provides for the novel pharmaceutical compositions of the compounds of Formula I.
  • the invention provides a method of inhibiting PDE IV which comprises administering to a subject in need thereof, a compound of Formula (I).
  • the invention further provides a method for the treatment of allergic and inflammatory disease which comprises administering to a subject in need thereof, an effective amount of a compound of Formula (I).
  • the invention also provides a method for the treatment of asthma which comprises administering to a subject in need thereof, an effective amount of a
  • the compounds of Formula (I) are useful in treating, prophylactically or therapeutically, disease states in humans which are exacerbated or caused by excessive or unregulated TNF production.
  • the present invention also provides a method for the inhibition of the production of tumor necrosis factor (TNF) in an animal in need thereof, including humans, which comprises administering to the animal in need of such treatment an effective amount of a compound of Formula I.
  • TNF tumor necrosis factor
  • TNF mediated disease states any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1, or IL-6.
  • IL-1 for instance is a major component, and whose
  • TNF tumor necrosis factor
  • cytokine any secreted polypeptide that affects the functions of other cells, and is a molecule which modulates
  • a cytokine includes, but is not limited to monokines and lymphokines regardless of which cells produce them.
  • a monokine is generally referred to as being produced and secreted by a
  • mononuclear cell such as a macrophage and/or monocyte but many other cells produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epidermal keratinocytes, and ⁇ -lymphocytes.
  • monokines such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epidermal keratinocytes, and ⁇ -lymphocytes.
  • Lymphokines are generally referred to as being produced by lymphocyte cells.
  • cytokines for the present invention include, but are not limited to
  • Interleukin-1 Interleukin-1
  • Interleukin-6 Interleukin-6
  • Tumor Tumor
  • TNFGC Tumor Necrosis Factor-alpha
  • TNF ⁇ Tumor Necrosis Factor beta
  • a preferred subgroup of formula I is formula (lb):
  • R 1 is C 4 -C 6 cyclic alkyl, unsubstituted or substituted by one to three methyl or ethyl groups;
  • C 1-7 alkyl unsubstituted or substituted by 1 to 3 fluorines; -(CH 2 ) s C(O)O- (CH 2 ) m CH 3 ; -(CH 2 ) s O (CH 2 ) m CH 3 ;
  • s 2 to 4.
  • n 0 to 2;
  • X is -YR 2 , halogen, nitro, amine, C 1-2 dialkylamine, C 1-2 monoalkylamine, or formyl amine;
  • Y is 0 or S(O) m ;
  • R 2 is -CH 3 or -CH 2 CH 3 , each may be
  • R 3 is H, CH 3 , CN, F, OH, -C ⁇ CR 9 or CF 3 ;
  • X 1 is O or S
  • q is 0 or 1
  • R 4 is independently hydrogen, Br, F, C1l -NR 5 R 16 , NO 2 , -C(Z)R 7 , -S(O) m C 1-3 alkyl, CN, OR 16,
  • R 5 is independently hydrogen or C 1-4 alkyl unsubstituted or substituted by one to three fluorines;
  • R 6 is H, R 12 , -C(O)R 12 , -C(O)C(O)R 7 ,
  • R 7 is OR 5 , NR 5 R 16 or R 12 ;
  • R 8 is H or -C(O)R 7 ;
  • R 9 is hydrogen, F or R 12 ;
  • R 12 is C 1-4 alkyl unsubstituted or substituted by one to three fluorines
  • R 14 is H or a C 1-2 alkyl unsubstituted or substituted by one or more fluorines;
  • R 15 is C 1-4 alkyl unsubstituted or substituted by one or more halogens; -C(O)C ⁇ -4 alkyl, unsubstituted or substituted by one or more halogens; oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morphollinyl, piperidinyl, piperazinyl, or pyrrolyl, and each of the heterocyclics may be unsubstituted or substituted by one or two C ⁇ _2 alkyl groups;
  • R 16 is OR 5 or R 5; or a pharmaceutically acceptable salt thereof;
  • Preferred compounds are those in which R 1 is
  • R 3' is hydrogen; X 3 is hydrogen; A is (a); R 4 is H, Br, OR 16 , CN, NR 5 R 6 , NO 2 , C(O)R 7 , S(O) m R 12 , 1- or 2- imidazolyl, -OC(O)CH 3 or NHC(O)R 15 ; R 8 is C(O)OH, H or C(O)OEt; R 14 is hydrogen, CH 3 , NH 2 or NHC(O)CH 3 .
  • R2 is methyl or fluoro substituted
  • R 3 is hydrogen, C ⁇ CH or CN; and R 4 is hydrogen, Br, NH 2, -NHC(O)CH 3 , C(O)OH, -NHC(NCN) SCH 3 , -NHC(O)NH 2 , -N(CH 3 ) 2r NHC(O)C(O)OCH 3 , -NHC (O) C (O) OH, -NHS(O) 2 CH 3 , -C(O)OCH 3 , S(O) 2 CH 3 , SCH 3 , -NHC(O)C(O)CH 3 , S(O)CH 3 , -NHC(O)C(O)NH 2 , CN, C(O)NH 2 , NHS(O) 2 CF 3 ,
  • R 1 is cyclopentyl, CF 3 , CH 2 F, CHF 2 , CF 2 CHF 2 , CH 2 CF 3 , CH 2 CHF 2 , CH 3 , CH 2 -cyclopentyl, CH 2 -cyclopropyl or cyclopentenyl;
  • R 2 is CF 3 , CHF 2 , or CH 2 CHF 2 ;
  • one R 3 is hydrogen and the other R 3 is hydrogen, C ⁇ CH or CN and is in the
  • X 2 R 1 , X and X 3 respectively represent X2R 1 , X and X 3 as defined in relation to Formula (I) or groups convertable to X 2 R 1, X and X 3 ; and X 1 is H, with an appropriate malonic acid ester derivative, such as
  • R 3' is H or COOR 17 , typically as a mixture.
  • Formula (2) with, e.g., carboalkoxy- or carboaryloxy-methylene trialkyl- or triarylphosphorane, provides a compound of the Formula (3) wherein R 18 is H.
  • a suitable solvent such as an aqueous alcohol
  • a source of cyanide such as sodium, potassium or tetra-alkylammonium cyanide
  • R 3' is H.
  • R 3' is COOR 17 , which may be hydrolyzed and decarboxylated to provide a compound of the Formula (5) wherein R 3' is H.
  • compounds of the Formula (5) wherein R 3' is H may be derived from first,
  • reaction of a compound of the Formula (9) (as described below) wherein R 20 is H and R 3 is H, R 12 or cyclopropyl unsubstituted or substituted by R 9 with a strong base, followed by reaction with an appropriate alkyl or aryl ⁇ -halo carboxylate, such as methyl ⁇ -bromoacetate, will also provide a compound of the Formula (4) wherein R 3 is H, R 12 or cyclopropyl unsubstituted or substituted by R 9 .
  • Reduction of the nitrile group of such compounds of the above Formula (4) or of the nitro group of the above similar compounds of the Formula (5) provides compounds of Formula (7) wherein R 19 is H.
  • R 19 is H; reaction of appropriate compounds of the Formula (8) wherein R 19 is H with a strong base, such as sodium hydride, followed by reaction of the generated amide anion with an appropriate activated alkylating agent, such as a halide, mesylate or tosylate, also provides the
  • X 4 is chloro or bromo and R 3 and R 20 are H;
  • a compound of the Formula (9) wherein R 3 is COOR 17 ,R 20 is H and X 4 is CN may also be obtained by reaction of a compound of the Formula (9) wherein R 3 and R 20 are H and X 4 is CN with a metal hydride, such as sodium hydride, in the presence of a dialkyl or diary1 carbonate, such as dimethyl carbonate.
  • a metal hydride such as sodium hydride
  • such compounds may be obtained by homologation of a compound of the Formula (2) wherein R 3 is H to a compound of the Formula (9) wherein R 3 is COOR 17 and X4 and R 20 are H by any number of known processes, such as reaction with methyl methylsulfinylmethyl sulfide and a base, e.g., sodium hydroxide, followed by treatment with, e.g., alcoholic acid.
  • a suitable base followed by reaction with, e.g., cyanogen chloride or 2-chlorobenzyl thiocyanate, provides compounds of the Formula (9) wherein R 3 is COOR 17 , R 20 is H and X 4 is CN.
  • Formula (7) compounds wherein R 19 is H and R 3 is the protected or unprotected hydroxyl.
  • These Formula (7) compounds may be alkylated on nitrogen and cyclized as described above,then treated with diethylaminosulfur trifluoride to provide the
  • compounds of Formula (la) wherein R 3 represents the remaining R 3 groups of Formula (la) may be derived from the compounds of the Formulas (8) or (la) wherein R 3 is CN by protection of the amide and other sensitive functionality, and manipulation of the CN function as, for example, reduction of the R 3 CN moiety to CHO and functional group transformation of the CHO by any of the standard conditions well known in the art.
  • Formula (2) compounds where R 3 is CH 2 F are obtained by treatment of the Formula (2) compounds where R 3 is CH 3 according to the method of Rozen et al.,
  • X is S(O) m R 12
  • m is 1 or 2
  • the final compound is made from the -SR 12 moiety by oxidizing the intermediate -SR 12 product under conditions well known to those skilled in the art, after the appropriate CONH 2 moiety in the synthetic sequence is dehydrated to the cyano moiety.
  • X and/or X 3 are Br, I, nitro, amine or formyl amine
  • synthesis of these compounds is accomplished by any of the steps described above using a suitably protected amine as X and/or X 3 .
  • Such protecting groups are known to those skilled in the art and are readily disclosed in Greene, T., Protective Groups in Organic Synthesis,
  • the deprotected amine is then appropriately acylated to the formyl amine moiety, oxidized to the NO 2 moiety, or diazotized and displaced by methods well known to those skilled in the art to produce the desired Br or I moiety.
  • Compounds of formula (I) and their pharmaceutically acceptable salts may be administered in standard manner for the treatment of the indicated diseases, for example orally, parenterally, sublingually, transdermally, rectally, via inhalation or via buccal administration.
  • compositions which are active when given orally can be formulated as syrups tablets, capsules and lozenges.
  • a syrup formulation will be formulated as
  • compositions generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent.
  • a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent.
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, agar, pectin, acacia, stearic acid, starch, lactose and sucrose.
  • composition is in the form of a capsule
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be
  • aqueous gums celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as
  • a typical suppository formulation comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their
  • Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose.
  • Each dosage unit for oral administration contains suitably from 0.001 mg to 100 mg/Kg, and preferably
  • parenteral administration contains suitably from 0.001 mg/Kg to 40 mg/Kg, of a compound of formula (I) or a pharmaceutically acceptable salt therof calculated as the free base.
  • Each dosage unit for intranasal contains suitably from 0.001 mg/Kg to 40 mg/Kg, of a compound of formula (I) or a pharmaceutically acceptable salt therof calculated as the free base.
  • administration or oral inhalation contains suitably
  • topical formulation contains suitably 001 to 1.0% of a compound of formula (I).
  • Each dosage unit for rectal administration contains suitably 0.01 mg to 100 mg of a compound of formula (I).
  • administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of formula (I) or a pharmaceutically
  • the daily dosage regimen for parenteral administration is suitably abut 0.001 mg/Kg to 40 mg/Kg, for example abut 0.001 mg/Kg to 40 mg/Kg, of a compound of the
  • inhalation is suitably about 10 to about 1200 mg/person.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit antiinflammatory
  • the active ingredient is administered in an amount sufficient to inhibit TNF production such that normal or subnormal levels are achieved which are sufficient to ameliorate or prevent the disease state.
  • selectivity of compounds is determined using a battery of five distinct PDE isozymes.
  • PDEs la, lb, Ic and III are partially purified using standard
  • PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-Sepharose chromatography (Torphy et al., J. Biol. Chem., 267: 1798-1804 (1992)).
  • IC 50 s for compounds of this invention range from 25 nM to 500 ⁇ M..
  • cAMP Accumulation in U-937 Cells The ability of selected PDE IV inhibitors to increase cAMP accumulation in intact tissues is assessed using ⁇ -937 cells, a human monocyte cell line that has been shown to contain a large amount of PDE IV. To assess the activity of PDE IV inhibition in intact cells, nondifferentiated U-937 cells (approximately 10 5 cells/reaction tube) were incubated with various concentrations (0.01-100 ⁇ M) of PDE inhibitors for one minute and 1 ⁇ M
  • prostaglandin E2 for an additional four minutes. Five minutes after initiating the reaction, cells were lysed by the addition of 1M potassium
  • Monocytes may be determined by the protocol as described in Badger et al., EPO published Application 0 411 754 A2, February 6, 1991, and in Hanna, WO 90/15534,
  • bromocyclopentane (32 mL, 0.31 mol) in dimethylformamide (0.25 L) was heated under an argon atmosphere at 100°C. After 4 h, additional bromocyclopentane (8 mL, 0.08 mol) was added and heating was continued for 4 h. The mixture was allowed to cool and was filtered. The filtrate was concentrated under reduced pressure and the residue was partitioned between ether and aqueous sodium carbonate. The organic extract was washed with aqueous sodium carbonate and dried (potassium carbonate). The solvent was removed in vacuo and the residue was
  • tetrahydrofuran (9mL) was treated with ammonium formate (1.04 g, 16.4 mmol) and 10% palladium on carbon (127 mg) in a suspension of methanol (25 mL). The suspension was stirred for three hours. The reaction was then filtered through celite and washed with methanol. The solvent was removed in vacuo and the residue was partitioned between methylene chloride and water. After extracting, the organic layer was washed two time with water, dried (potassium carbonate) and concentrated in vacuo .
  • the solvent was removed in vacuo and the residue was treated with cold water and extracted twice with methylene chloride.
  • the organic layer was washed two times with water, dried (potassium carbonate) and concentrated in vacuo .
  • the resin was purified by flash chromatography, eluting with a gradient of 50-100% ethyl acetate/methylene chloride to provide a colorless oil of the title compound (396 mg, 82%).
  • Methyl 3-cyano-3-(3,4-dimethoxyphenyl)propionate (3.0 g, 12 mmol) and 70% perchloric acid (1.9 g) were added to a suspension of 10% palladium on carbon (0.6 g) in
  • the aqueous layer was extracted, the combined organic phase washed with water and dried (sodium sulfate).
  • the solvent was removed in vacuo, and the residue was dissolved in toluene with a catalytic amount of sodium cyanide and was refluxed for 7 h.
  • the solvent was removed in vacuo the residue was dissolved in ethyl acetate and washed with water two times.
  • the organic layer was dried (sodium sulfate) and evaporated.
  • the solvent was removed in vacuo and the residue was dissolved in toluene with a catalytic amount of sodium cyanide and refluxed for 15 hours.
  • the solvent was removed in vacuo, the residue was partitioned between ethyl acetate and water and the organic layer washed with water two times.
  • the organic layer was dried (sodium sulfate) and evaporated.
  • the residue was purified by flash chromatography, eluting with 1:1% ethyl acetate/hexanes, to provide the product (468 mg, 69%).
  • reaction was quenched by adding solid sodium bicarbonate and the reaction mixture was partitioned between methylene chloride and water.
  • the reaction mixture was concentrated in vacuo, water added and the aqueous phase extracted three times with methylene chloride. The extracts were washed with water two times, dried (sodium sulfate) and evaporated to a yellow residue. The residue was
  • reaction mixture was allowed to stir for 24 h at room temperature under an argon atmosphere, and submitted to another two cycles of treatment with acetic anhydride (200 mL, 2.2 mmol; 400 ⁇ L, 4.4 mmol).
  • acetic anhydride 200 mL, 2.2 mmol; 400 ⁇ L, 4.4 mmol.
  • the reaction was poured into ice cold aqueous hydrochloric acid and extracted twice with methylene chloride. The organic extracts were washed with cold dilute
  • EXAMPLE 48 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-[4-(4,4- dimethyl-2-oxazolin-2-ylcarbonylamino)benzyl]-2- pyrrolidinone a) 4-(3-Cyclopentyloxy-4-methoxyphenyl)-1-[4-(N-1-hydroxy-2-methyl-2-propylcarbamidocarbamido)benzyl]-2-pyrrolidinone To a solution of 1-(4-N-carbomethoxycarbamidobenzyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidinone (0.125 g, 0.27 mmol) in alumina-treated chloroform (10 mL) was added 2-amino-2-methylpropanol (0.051 mL, 0.54 mmol) and the mixture was stirred under an argon atmosphere overnight.
  • Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
  • a compound of formula I, (1 ⁇ g to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Step 1 Blend ingredients No. 1, No. 2, No . 3 and No .
  • Step 2 Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
  • Step 3 The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • Step 4 The wet granules are then dried in an oven at
  • Step 5 The dry granules are lubricated with
  • Step 6 The lubricated granules are compressed on a suitable tablet press.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount f a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouvelles pyrrolidinones qui inhibent PDE IV et TNF.
PCT/US1992/003613 1991-05-02 1992-05-01 Pyrrolidinones Ceased WO1992019594A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4511481A JPH06507405A (ja) 1991-05-02 1992-05-01 ピロリジノン類

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69462491A 1991-05-02 1991-05-02
US694,624 1991-05-02

Publications (1)

Publication Number Publication Date
WO1992019594A1 true WO1992019594A1 (fr) 1992-11-12

Family

ID=24789624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/003613 Ceased WO1992019594A1 (fr) 1991-05-02 1992-05-01 Pyrrolidinones

Country Status (10)

Country Link
EP (1) EP0584208A1 (fr)
JP (1) JPH06507405A (fr)
CN (1) CN1067244A (fr)
AU (1) AU1917092A (fr)
CA (1) CA2102106A1 (fr)
IE (1) IE921376A1 (fr)
MX (1) MX9202090A (fr)
PT (1) PT100441A (fr)
WO (1) WO1992019594A1 (fr)
ZA (1) ZA923210B (fr)

Cited By (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012461A1 (fr) * 1992-12-02 1994-06-09 Pfizer Inc. Diethers de pyrocatechine utilises comme inhibiteurs selectifs de la pde¿iv?
WO1994014742A1 (fr) * 1992-12-23 1994-07-07 Celltech Limited Derives du phenyle tri-substitue utilises comme inhibiteurs de la phosphodiesterase
WO1995008534A1 (fr) * 1993-09-20 1995-03-30 Glaxo Wellcome Inc. 3-(3,4-dioxyphenyl)-pyrrolidines utilises comme inhibiteurs de la phosphodiesterase de type iv pour traiter les maladies inflammatoires
EP0671389A1 (fr) * 1994-03-08 1995-09-13 Mitsubishi Chemical Corporation Dérivés de la 3-phènylpyrrolidine
WO1995028926A1 (fr) * 1994-04-21 1995-11-02 Schering Aktiengesellschaft Inhibiteurs de pde iv utilises dans le traitement de la sclerose en plaques
US5491147A (en) * 1992-10-23 1996-02-13 Celltech, Limited Tri-substituted phenyl derivatives and their use in pharmaceutical compositions and methods of treatment
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5580888A (en) * 1992-12-23 1996-12-03 Celltech Therapeutics Limited Styryl derivatives as anti-inflammatory agents
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5608070A (en) * 1993-12-22 1997-03-04 Celltech Therapeutics Limited Enantioselective process for the preparation of chiral triaryl derivatives and chiral intermediates for use therein
WO1997012859A1 (fr) * 1995-10-06 1997-04-10 Celgene Corporation Succinimides et maleimides inhibiteurs de la cytokine
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
US5633257A (en) * 1993-03-10 1997-05-27 Celltech Therapeutics Limited Cyclo(alkyl and alkenyl)phenyl-alkenylyl(aryl and heteroaryl)compounds and pharmaceutical compositions containing them
US5665737A (en) * 1994-10-12 1997-09-09 Euro-Celtique, S.A. Substituted benzoxazoles
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5686434A (en) * 1993-11-26 1997-11-11 Pfizer Inc. 3-aryl-2-isoxazolines as antiinflammatory agents
US5693659A (en) * 1994-06-23 1997-12-02 Celltech Therapeutics Limited Substituted oxime derivatives and processes for their preparation
US5696141A (en) * 1994-03-09 1997-12-09 Pfizer Inc. Isoxazoline compounds as 5-lipoxygenase inhibitors
US5716967A (en) * 1993-11-26 1998-02-10 Pfizer Inc. Isoxazoline compounds as antiinflammatory agents
US5739144A (en) * 1993-03-10 1998-04-14 Celltech Therapeutics Limited Trisubstituted phenyl derivatives
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
US5780478A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Tetra-substituted phenyl derivatives
US5780477A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US5798373A (en) * 1995-12-21 1998-08-25 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
WO1998042666A1 (fr) * 1997-03-21 1998-10-01 Daewoong Pharmaceutical Co., Ltd. Derives 3,4-dialcoxyphenyle et leur utilisation
US5840724A (en) * 1993-06-01 1998-11-24 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or
US5849770A (en) * 1995-12-21 1998-12-15 Celltech Therapeutics Ltd. Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5859034A (en) * 1996-12-04 1999-01-12 Celltech Therapeutics, Limited Tri-substituted phenyl compounds which have useful pharmaceutical activity
EP0710109A4 (fr) * 1993-06-18 1999-01-20 Smithkline Beecham Corp Composes
US5866593A (en) * 1993-12-22 1999-02-02 Celltech Therapeutics Ltd. Trisubstituted phenyl derivatives and processes for their preparation
US5869511A (en) * 1994-03-09 1999-02-09 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
US5922741A (en) * 1996-04-24 1999-07-13 Celltech Therapeutics Ltd. 5-aminopyrazoles useful as tyrosine kinase inhibitors
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6025376A (en) * 1995-10-20 2000-02-15 Schering Aktiengesellschaft Chiral methylphenyloxazolidinones
US6040329A (en) * 1996-06-25 2000-03-21 Pfizer Inc Substituted indazole analogs
US6048866A (en) * 1997-03-14 2000-04-11 Celltech Therapeutics, Limited Substituted 2-anilinopryimidines useful as protein kinase inhibitors
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US6090816A (en) * 1994-12-13 2000-07-18 Euro-Celtique S.A. Aryl thioxanthines
US6093716A (en) * 1996-09-16 2000-07-25 Celltech Therapeutics, Limited Substituted 2-pyrimidineamines and processes for their preparation
US6096747A (en) * 1992-06-15 2000-08-01 Celltech Therapeutics Limited Phenylaminocarbonyl derivatives and processes for their preparation
US6114333A (en) * 1996-10-28 2000-09-05 Celltech Therapeutics Ltd. 2-Pyrimidineamine derivatives and processes for their preparation
US6117895A (en) * 1995-02-10 2000-09-12 Schering Aktiengesellschaft Pharmaceutical preparations for TNF inhibition
US6133257A (en) * 1997-06-20 2000-10-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
WO2001046136A1 (fr) * 1999-12-23 2001-06-28 Icos Corporation Derives oxime et hydrazone de pyrrolidines inhibiteurs de phosphodiesterase specifique d'amp
US6255326B1 (en) 1991-01-28 2001-07-03 Aventis Pharma Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
WO2001047880A1 (fr) * 1999-12-23 2001-07-05 Icos Corporation Inhibiteurs de phosphodiesterase specifiques a l'amp cyclique
WO2001047879A1 (fr) * 1999-12-23 2001-07-05 Icos Corporation Pyrrolidines inhibitrices de la phosphodiesterase specifique d'amp cyclique
WO2001049684A1 (fr) * 2000-01-06 2001-07-12 Sanofi-Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
WO2001068600A3 (fr) * 2000-03-16 2002-02-28 Inflazyme Pharm Ltd Inhibiteurs benzyles de pde4
WO2002000593A3 (fr) * 2000-06-23 2002-05-16 Sigma Tau Ind Farmaceuti Composes utiles pour la preparation de medicaments exerçant une activite d'inhibition de la phosphodiesterase iv
WO2002081447A1 (fr) * 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. Derives de 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone et utilisation de ces derives
WO2002081446A1 (fr) * 2001-04-06 2002-10-17 Daewoong Co., Ltd. Derives 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone et utilisation
FR2823748A1 (fr) * 2001-04-20 2002-10-25 Sanofi Synthelabo Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2003032981A1 (fr) 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation Derives 4-(4-alcoky-3-hydroxyphenyle)-2-pyrrolidone utilises en tant qu'inhibiteurs de la pde4 pour le traitement de syndromes neurologiques
US6579983B1 (en) 1999-06-18 2003-06-17 Celltech R&D Limited 5-cyano-2-aminopyrimidine derivatives
US6600037B1 (en) 1999-10-20 2003-07-29 Celltech R & D Limited 4,5-disubstituted-2-aminopyrimidines
EP1380291A1 (fr) * 1994-04-21 2004-01-14 Schering Aktiengesellschaft Inhibiteurs de PDE IV pour le traitement de la sclérose en plaques
US6680336B2 (en) 1999-12-15 2004-01-20 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2004011429A1 (fr) * 2002-07-26 2004-02-05 Nihon Nohyaku Co., Ltd. Nouveaux derives d'haloalkylsulfonanilide, herbicides et utilisation de ceux-ci
WO2004094375A3 (fr) * 2003-04-16 2005-04-21 Memory Pharm Corp Inhibiteurs de la phosphodiesterase 4
US7045660B2 (en) 1993-07-28 2006-05-16 Aventis Pharma Limited Compounds as PDE IV and TNF-inhibitors
WO2006056471A1 (fr) 2004-11-29 2006-06-01 Novartis Ag Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2
US7199243B2 (en) 2002-11-26 2007-04-03 Pfizer Inc. Piperidine compounds useful as PPAR activators
US7226930B2 (en) 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
US7235561B2 (en) 2001-05-29 2007-06-26 Schering Ag Compound and a composition including such a compound
WO2007071400A1 (fr) 2005-12-22 2007-06-28 Novartis Ag Derives de pyrazine en tant que bloqueur du canal sodique epithelial
WO2007121920A2 (fr) 2006-04-21 2007-11-01 Novartis Ag Composés organiques
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
WO2008052734A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composés hétérocycliques en tant qu'agents anti-inflammatoires
US7432266B2 (en) 2004-10-15 2008-10-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
US7585882B2 (en) 2004-10-20 2009-09-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2123306A1 (fr) 2004-12-03 2009-11-25 Fondazione Telethon Utilisation d'une protéine de leurre qui interfère avec la voie de signalisation Hedgehog pour la fabrication d'un médicament pour empêcher, inhiber, et/ou inverser les maladies oculaires associées à la néovascularisation oculaire
WO2009150137A2 (fr) 2008-06-10 2009-12-17 Novartis Ag Composés organiques
EP2206499A1 (fr) 2004-11-02 2010-07-14 Novartis AG Derives de quinuclidine et leur utilisation en tant qu'antagonistes des recépteurs muscariniques m3
WO2010088335A1 (fr) 2009-01-29 2010-08-05 Novartis Ag Benzimidazoles substitués destinés au traitement d'astrocytomes
EP2253612A1 (fr) 2005-04-14 2010-11-24 Novartis AG Composés organiques
EP2270008A1 (fr) 2005-05-20 2011-01-05 Novartis AG 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones comme inhibiteurs de kinases lipidiques et/ou de la pi3 kinase
EP2279777A2 (fr) 2007-01-10 2011-02-02 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéase à activation de canal
EP2281819A1 (fr) 2004-01-21 2011-02-09 Novartis AG Dérivés du benzimidazole ou du benzoxazole
WO2011015652A1 (fr) 2009-08-07 2011-02-10 Novartis Ag Dérivés 3-hétéroarylméthyl-imidazo[1,2-b]pyridazin-6-yliques comme modulateurs de la tyrosine kinase c-met
WO2011018454A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composés hydrazone hétérocycliques et leurs utilisations pour traiter le cancer et l'inflammation
EP2286813A2 (fr) 2006-01-31 2011-02-23 Novartis AG Utilisation de dérivés de naphthyridine comme medicaments
WO2011022439A1 (fr) 2009-08-17 2011-02-24 Intellikine, Inc. Composés hétérocycliques et leurs utilisations
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
EP2292619A1 (fr) 2004-10-22 2011-03-09 Novartis AG Derivés de purin et leurs utilisation comme agonists d'adenosin-A2A-récepteur
WO2011050325A1 (fr) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques
EP2332933A1 (fr) 2007-05-07 2011-06-15 Novartis AG Inhibiteurs du canal sodique épithélial
WO2011113894A1 (fr) 2010-03-19 2011-09-22 Novartis Ag Dérivés de pyridine et de pyrazine pour le traitement de la mucoviscidose
WO2012034091A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions à titre d'inhibiteurs de trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012035158A1 (fr) 2010-09-17 2012-03-22 Novartis Ag Dérivés de la pyrazine en tant que bloqueurs de l'enac
EP2444120A1 (fr) 2007-12-10 2012-04-25 Novartis AG Analogues d'Amiloride spirocyclique en tant que blocker d'ENaC
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
EP2532679A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
WO2013030802A1 (fr) 2011-09-01 2013-03-07 Novartis Ag Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
WO2013038390A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Hétérocyclyle carboxamides n-substitués
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038362A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
WO2013140319A1 (fr) 2012-03-19 2013-09-26 Novartis Ag Forme cristalline d'un sel de succinate
WO2013149581A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2014132220A1 (fr) 2013-03-01 2014-09-04 Novartis Ag Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2015162459A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162456A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162461A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
WO2016011956A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
WO2016016822A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polythérapie
EP3603634A1 (fr) 2004-05-18 2020-02-05 Novartis AG Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique
WO2020250116A1 (fr) 2019-06-10 2020-12-17 Novartis Ag Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie
WO2021038426A1 (fr) 2019-08-28 2021-03-04 Novartis Ag Dérivés de 1,3-phényl hétéroaryle substitués et leur utilisation dans le traitement d'une maladie
CN114558002A (zh) * 2022-03-15 2022-05-31 四川轻化工大学 化合物在制备治疗肿瘤药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004107323A (ja) * 2002-07-26 2004-04-08 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体及び除草剤並びにその使用方法
EP1810692A1 (fr) * 2004-10-13 2007-07-25 Kyowa Hakko Kogyo Co., Ltd. Traitements prophylactiques ou thérapeutiques de maladie chronique de la peau
CA2584261A1 (fr) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Preparation pharmaceutique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4916872A (fr) * 1972-04-21 1974-02-14
JPS5232064B2 (fr) * 1972-06-14 1977-08-19
JPS5238227B2 (fr) * 1972-06-14 1977-09-28
JPS5182258A (ja) * 1974-04-25 1976-07-19 Yoshitomi Pharmaceutical Pirorijinonjudotaino seizoho
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0584208A4 *

Cited By (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255326B1 (en) 1991-01-28 2001-07-03 Aventis Pharma Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US6096747A (en) * 1992-06-15 2000-08-01 Celltech Therapeutics Limited Phenylaminocarbonyl derivatives and processes for their preparation
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5491147A (en) * 1992-10-23 1996-02-13 Celltech, Limited Tri-substituted phenyl derivatives and their use in pharmaceutical compositions and methods of treatment
US6080790A (en) * 1992-10-23 2000-06-27 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparations
US5674880A (en) * 1992-10-23 1997-10-07 Celltech Therapeutics Limited Tri-substituted phenyl derivatives and processes for their preparation
JP3100984B2 (ja) 1992-12-02 2000-10-23 ファイザー・インク． 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
WO1994012461A1 (fr) * 1992-12-02 1994-06-09 Pfizer Inc. Diethers de pyrocatechine utilises comme inhibiteurs selectifs de la pde¿iv?
AU673569B2 (en) * 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
GB2279075B (en) * 1992-12-23 1997-03-05 Celltech Ltd Tri-substituted phenyl derivatives as phosphodiesterase inhibitors
WO1994014742A1 (fr) * 1992-12-23 1994-07-07 Celltech Limited Derives du phenyle tri-substitue utilises comme inhibiteurs de la phosphodiesterase
US5580888A (en) * 1992-12-23 1996-12-03 Celltech Therapeutics Limited Styryl derivatives as anti-inflammatory agents
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
CN1054603C (zh) * 1992-12-23 2000-07-19 塞尔特奇公司 三取代的苯基衍生物及含有该衍生物的药物组合物
GB2279075A (en) * 1992-12-23 1994-12-21 Celltech Ltd Tri-substituted phenyl derivatives as phosphodiesterase inhibitors
US5739144A (en) * 1993-03-10 1998-04-14 Celltech Therapeutics Limited Trisubstituted phenyl derivatives
US5723460A (en) * 1993-03-10 1998-03-03 Celltech Therapeutics Limited Cyclo (alkyl and alkenyl) phenyl-alkenylyl heteroaryl compounds and pharmaceutical compositions containing same
US5633257A (en) * 1993-03-10 1997-05-27 Celltech Therapeutics Limited Cyclo(alkyl and alkenyl)phenyl-alkenylyl(aryl and heteroaryl)compounds and pharmaceutical compositions containing them
US5962483A (en) * 1993-03-10 1999-10-05 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US5962492A (en) * 1993-03-10 1999-10-05 Celltech Therapeutics Limited 2 cyclo(alkyl and alkenyl) phenyl-alkenylyl heteroaryl compounds and pharmaceutical compositions containing same
US5840724A (en) * 1993-06-01 1998-11-24 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or
US6143782A (en) * 1993-06-18 2000-11-07 Smithkline Beecham Corporation Anti-inflammatory and anti-asthma treatment with reduced side effects
EP0710109A4 (fr) * 1993-06-18 1999-01-20 Smithkline Beecham Corp Composes
EP1466598A3 (fr) * 1993-06-18 2007-06-27 Smithkline Beecham Corporation Inhibiteurs de pde 4
US7045660B2 (en) 1993-07-28 2006-05-16 Aventis Pharma Limited Compounds as PDE IV and TNF-inhibitors
US7652144B2 (en) 1993-07-28 2010-01-26 Aventis Pharma Limited Compounds as PDE IV and TNF inhibitors
WO1995008534A1 (fr) * 1993-09-20 1995-03-30 Glaxo Wellcome Inc. 3-(3,4-dioxyphenyl)-pyrrolidines utilises comme inhibiteurs de la phosphodiesterase de type iv pour traiter les maladies inflammatoires
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5686434A (en) * 1993-11-26 1997-11-11 Pfizer Inc. 3-aryl-2-isoxazolines as antiinflammatory agents
US5716967A (en) * 1993-11-26 1998-02-10 Pfizer Inc. Isoxazoline compounds as antiinflammatory agents
US5608070A (en) * 1993-12-22 1997-03-04 Celltech Therapeutics Limited Enantioselective process for the preparation of chiral triaryl derivatives and chiral intermediates for use therein
US5866593A (en) * 1993-12-22 1999-02-02 Celltech Therapeutics Ltd. Trisubstituted phenyl derivatives and processes for their preparation
US5545647A (en) * 1994-03-08 1996-08-13 Mitsubishi Chemical Corporation 3-phenylpyrrolidine derivatives
EP0671389A1 (fr) * 1994-03-08 1995-09-13 Mitsubishi Chemical Corporation Dérivés de la 3-phènylpyrrolidine
US5696141A (en) * 1994-03-09 1997-12-09 Pfizer Inc. Isoxazoline compounds as 5-lipoxygenase inhibitors
US5869511A (en) * 1994-03-09 1999-02-09 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
US5847010A (en) * 1994-04-21 1998-12-08 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
WO1995028926A1 (fr) * 1994-04-21 1995-11-02 Schering Aktiengesellschaft Inhibiteurs de pde iv utilises dans le traitement de la sclerose en plaques
EP1380291A1 (fr) * 1994-04-21 2004-01-14 Schering Aktiengesellschaft Inhibiteurs de PDE IV pour le traitement de la sclérose en plaques
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US6077854A (en) * 1994-06-21 2000-06-20 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US5780478A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Tetra-substituted phenyl derivatives
US6197792B1 (en) 1994-06-22 2001-03-06 Celltech Therapeutics Limited Tetra-substituted phenyl derivatives and processes for their preparation
US5780477A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US6297264B1 (en) 1994-06-22 2001-10-02 Celltech Therapeutics Limited Trisubstituted phenyl derivatives and process for their preparation
US5693659A (en) * 1994-06-23 1997-12-02 Celltech Therapeutics Limited Substituted oxime derivatives and processes for their preparation
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5665737A (en) * 1994-10-12 1997-09-09 Euro-Celtique, S.A. Substituted benzoxazoles
US6090816A (en) * 1994-12-13 2000-07-18 Euro-Celtique S.A. Aryl thioxanthines
US6117895A (en) * 1995-02-10 2000-09-12 Schering Aktiengesellschaft Pharmaceutical preparations for TNF inhibition
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
WO1997012859A1 (fr) * 1995-10-06 1997-04-10 Celgene Corporation Succinimides et maleimides inhibiteurs de la cytokine
US6025376A (en) * 1995-10-20 2000-02-15 Schering Aktiengesellschaft Chiral methylphenyloxazolidinones
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US6235746B1 (en) 1995-11-20 2001-05-22 Celltech Therapeutics, Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US5849770A (en) * 1995-12-21 1998-12-15 Celltech Therapeutics Ltd. Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5798373A (en) * 1995-12-21 1998-08-25 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5922741A (en) * 1996-04-24 1999-07-13 Celltech Therapeutics Ltd. 5-aminopyrazoles useful as tyrosine kinase inhibitors
US6040329A (en) * 1996-06-25 2000-03-21 Pfizer Inc Substituted indazole analogs
CN1080260C (zh) * 1996-06-25 2002-03-06 美国辉瑞有限公司 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
US6093716A (en) * 1996-09-16 2000-07-25 Celltech Therapeutics, Limited Substituted 2-pyrimidineamines and processes for their preparation
US6552029B1 (en) 1996-10-28 2003-04-22 Celltech R&D Limited 2-pyrimidineamine derivatives and processes for their preparation
US6114333A (en) * 1996-10-28 2000-09-05 Celltech Therapeutics Ltd. 2-Pyrimidineamine derivatives and processes for their preparation
US5859034A (en) * 1996-12-04 1999-01-12 Celltech Therapeutics, Limited Tri-substituted phenyl compounds which have useful pharmaceutical activity
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6599908B1 (en) 1996-12-23 2003-07-29 Celltech R & D Limited Fused polycyclic 2-aminopyrimidine derivatives
US6048866A (en) * 1997-03-14 2000-04-11 Celltech Therapeutics, Limited Substituted 2-anilinopryimidines useful as protein kinase inhibitors
US6337335B1 (en) 1997-03-14 2002-01-08 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO1998042666A1 (fr) * 1997-03-21 1998-10-01 Daewoong Pharmaceutical Co., Ltd. Derives 3,4-dialcoxyphenyle et leur utilisation
US6133257A (en) * 1997-06-20 2000-10-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6579983B1 (en) 1999-06-18 2003-06-17 Celltech R&D Limited 5-cyano-2-aminopyrimidine derivatives
US6600037B1 (en) 1999-10-20 2003-07-29 Celltech R & D Limited 4,5-disubstituted-2-aminopyrimidines
US6680336B2 (en) 1999-12-15 2004-01-20 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2001047880A1 (fr) * 1999-12-23 2001-07-05 Icos Corporation Inhibiteurs de phosphodiesterase specifiques a l'amp cyclique
AU778795B2 (en) * 1999-12-23 2004-12-23 Icos Corporation Pyrrolidines which inhibit cAMP-specific PDE
EA007589B1 (ru) * 1999-12-23 2006-12-29 Айкос Корпорейшен ПИРРОЛИДИНЫ, КОТОРЫЕ ИНГИБИРУЮТ цАМФ-СПЕЦИФИЧНУЮ PDE
WO2001047879A1 (fr) * 1999-12-23 2001-07-05 Icos Corporation Pyrrolidines inhibitrices de la phosphodiesterase specifique d'amp cyclique
US6500856B2 (en) 1999-12-23 2002-12-31 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2001046136A1 (fr) * 1999-12-23 2001-06-28 Icos Corporation Derives oxime et hydrazone de pyrrolidines inhibiteurs de phosphodiesterase specifique d'amp
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6569890B2 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6689797B2 (en) 2000-01-06 2004-02-10 Sanofi-Synthelabo Tetrahydropyridines, preparation method and pharmaceutical compositions containing same
KR100755103B1 (ko) * 2000-01-06 2007-09-04 사노피-아벤티스 신규 테트라히드로피리딘, 제조 방법 및 이를 함유하는제약 조성물
FR2803593A1 (fr) * 2000-01-06 2001-07-13 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2001049684A1 (fr) * 2000-01-06 2001-07-12 Sanofi-Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
CZ300658B6 (cs) * 2000-01-06 2009-07-08 Sanofi-Aventis Tetrahydropyridinový derivát, zpusob jeho prípravy, farmaceutická kompozice tento derivát obsahující a použití tohoto derivátu pro prípravu léciv
US6555572B2 (en) 2000-03-16 2003-04-29 Inflazyme Pharmaceuticals Ltd. Benzylated PDE4 inhibitors
US7446129B2 (en) 2000-03-16 2008-11-04 Biolipox Ab Benzylated PDE4 inhibitors
WO2001068600A3 (fr) * 2000-03-16 2002-02-28 Inflazyme Pharm Ltd Inhibiteurs benzyles de pde4
US7459479B2 (en) 2000-03-16 2008-12-02 Biolipox Ab Benzylated PDE4 inhibitors
WO2002000593A3 (fr) * 2000-06-23 2002-05-16 Sigma Tau Ind Farmaceuti Composes utiles pour la preparation de medicaments exerçant une activite d'inhibition de la phosphodiesterase iv
US7169808B2 (en) 2000-06-23 2007-01-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds useful for the preparation of medicaments with phosphodiesterase IV inhibitory activity
WO2002081447A1 (fr) * 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. Derives de 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone et utilisation de ces derives
WO2002081446A1 (fr) * 2001-04-06 2002-10-17 Daewoong Co., Ltd. Derives 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone et utilisation
FR2823748A1 (fr) * 2001-04-20 2002-10-25 Sanofi Synthelabo Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US7235561B2 (en) 2001-05-29 2007-06-26 Schering Ag Compound and a composition including such a compound
US7291624B2 (en) 2001-05-29 2007-11-06 Bayer Schering Pharma Ag CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
AU2002335015B8 (en) * 2001-10-16 2006-11-30 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US7235579B2 (en) 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
JP2009286797A (ja) * 2001-10-16 2009-12-10 Memory Pharmaceutical Corp 神経病症候群の治療の為のｐｄｅ−４阻害剤としての、４−（４−アルコキシ−３−ヒドロキシフェニル）−２−ピロリディン誘導体。
AU2002335015B2 (en) * 2001-10-16 2006-11-02 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
KR100951218B1 (ko) * 2001-10-16 2010-04-05 메모리 파마슈티칼스 코포레이션 신경계 증후군의 치료를 위한 ｐｄｅ-4 억제제로서의4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체
RU2340600C2 (ru) * 2001-10-16 2008-12-10 Мемори Фармасьютиклз Корпорейшн Производные 4-(4-алкокси-3-гидроксифенил)-2-пирролидона в качестве ингибиторов pde-4 для лечения неврологических синдромов
WO2003032981A1 (fr) 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation Derives 4-(4-alcoky-3-hydroxyphenyle)-2-pyrrolidone utilises en tant qu'inhibiteurs de la pde4 pour le traitement de syndromes neurologiques
WO2004011429A1 (fr) * 2002-07-26 2004-02-05 Nihon Nohyaku Co., Ltd. Nouveaux derives d'haloalkylsulfonanilide, herbicides et utilisation de ceux-ci
US7199243B2 (en) 2002-11-26 2007-04-03 Pfizer Inc. Piperidine compounds useful as PPAR activators
US7696198B2 (en) 2003-04-16 2010-04-13 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2004094375A3 (fr) * 2003-04-16 2005-04-21 Memory Pharm Corp Inhibiteurs de la phosphodiesterase 4
US7495017B2 (en) 2003-04-18 2009-02-24 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7226930B2 (en) 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
EP2281819A1 (fr) 2004-01-21 2011-02-09 Novartis AG Dérivés du benzimidazole ou du benzoxazole
EP3603634A1 (fr) 2004-05-18 2020-02-05 Novartis AG Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique
US7432266B2 (en) 2004-10-15 2008-10-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7723348B2 (en) 2004-10-15 2010-05-25 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7585882B2 (en) 2004-10-20 2009-09-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2292619A1 (fr) 2004-10-22 2011-03-09 Novartis AG Derivés de purin et leurs utilisation comme agonists d'adenosin-A2A-récepteur
EP2206499A1 (fr) 2004-11-02 2010-07-14 Novartis AG Derives de quinuclidine et leur utilisation en tant qu'antagonistes des recépteurs muscariniques m3
EP2305659A1 (fr) 2004-11-29 2011-04-06 Novartis AG Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2
WO2006056471A1 (fr) 2004-11-29 2006-06-01 Novartis Ag Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2
EP2123306A1 (fr) 2004-12-03 2009-11-25 Fondazione Telethon Utilisation d'une protéine de leurre qui interfère avec la voie de signalisation Hedgehog pour la fabrication d'un médicament pour empêcher, inhiber, et/ou inverser les maladies oculaires associées à la néovascularisation oculaire
EP2253612A1 (fr) 2005-04-14 2010-11-24 Novartis AG Composés organiques
EP2292617A1 (fr) 2005-05-20 2011-03-09 Novartis AG Dérivés de 1,3-dihydro-imidazo[4,5-c]quinolin-2-one comme inhibiteurs de kinase lipidique et/ou de kinase pi3
EP2270008A1 (fr) 2005-05-20 2011-01-05 Novartis AG 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones comme inhibiteurs de kinases lipidiques et/ou de la pi3 kinase
EP2532679A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
EP2532677A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
WO2007071400A1 (fr) 2005-12-22 2007-06-28 Novartis Ag Derives de pyrazine en tant que bloqueur du canal sodique epithelial
EP2286813A2 (fr) 2006-01-31 2011-02-23 Novartis AG Utilisation de dérivés de naphthyridine comme medicaments
EP2322525A1 (fr) 2006-04-21 2011-05-18 Novartis AG Derives de purine comme d'agonistes des recepteurs de l'adenosine A2A
WO2007121920A2 (fr) 2006-04-21 2007-11-01 Novartis Ag Composés organiques
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
WO2008052734A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composés hétérocycliques en tant qu'agents anti-inflammatoires
EP2279777A2 (fr) 2007-01-10 2011-02-02 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéase à activation de canal
EP2332933A1 (fr) 2007-05-07 2011-06-15 Novartis AG Inhibiteurs du canal sodique épithélial
EP2444120A1 (fr) 2007-12-10 2012-04-25 Novartis AG Analogues d'Amiloride spirocyclique en tant que blocker d'ENaC
EP2520574A1 (fr) 2007-12-10 2012-11-07 Novartis AG Analogues d'Amiloride substitués sur la partie cyclique de la guanidine en tant que bloqueurs d'ENaC pour le traitement de maladies respiratoires
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
WO2009150137A2 (fr) 2008-06-10 2009-12-17 Novartis Ag Composés organiques
WO2010088335A1 (fr) 2009-01-29 2010-08-05 Novartis Ag Benzimidazoles substitués destinés au traitement d'astrocytomes
WO2011015652A1 (fr) 2009-08-07 2011-02-10 Novartis Ag Dérivés 3-hétéroarylméthyl-imidazo[1,2-b]pyridazin-6-yliques comme modulateurs de la tyrosine kinase c-met
WO2011018454A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composés hydrazone hétérocycliques et leurs utilisations pour traiter le cancer et l'inflammation
WO2011022439A1 (fr) 2009-08-17 2011-02-24 Intellikine, Inc. Composés hétérocycliques et leurs utilisations
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
WO2011050325A1 (fr) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques
EP2813227A1 (fr) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques
US11911371B2 (en) 2010-03-19 2024-02-27 Novartis Ag Pyridine and pyrazine derivative for the treatment of chronic bronchitis
WO2011113894A1 (fr) 2010-03-19 2011-09-22 Novartis Ag Dérivés de pyridine et de pyrazine pour le traitement de la mucoviscidose
EP2845593A1 (fr) 2010-03-19 2015-03-11 Novartis AG Dérivé de pyridine et de pyrazine pour le traitement d'une maladie pulmonaire obstructive chronique
USRE46757E1 (en) 2010-03-19 2018-03-20 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US10117858B2 (en) 2010-03-19 2018-11-06 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9365552B2 (en) 2010-03-19 2016-06-14 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012034091A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions à titre d'inhibiteurs de trk
WO2012035158A1 (fr) 2010-09-17 2012-03-22 Novartis Ag Dérivés de la pyrazine en tant que bloqueurs de l'enac
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
WO2013030802A1 (fr) 2011-09-01 2013-03-07 Novartis Ag Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
WO2013038362A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038390A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Hétérocyclyle carboxamides n-substitués
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US9669032B2 (en) 2011-11-23 2017-06-06 Intellikine Llc Enhanced treatment regimens using mTOR inhibitors
WO2013140319A1 (fr) 2012-03-19 2013-09-26 Novartis Ag Forme cristalline d'un sel de succinate
WO2013149581A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
EP3964513A1 (fr) 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2014132220A1 (fr) 2013-03-01 2014-09-04 Novartis Ag Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2015162461A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162456A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2015162459A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2016011956A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
WO2016016822A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polythérapie
WO2020250116A1 (fr) 2019-06-10 2020-12-17 Novartis Ag Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie
WO2021038426A1 (fr) 2019-08-28 2021-03-04 Novartis Ag Dérivés de 1,3-phényl hétéroaryle substitués et leur utilisation dans le traitement d'une maladie
CN114558002A (zh) * 2022-03-15 2022-05-31 四川轻化工大学 化合物在制备治疗肿瘤药物中的应用

Also Published As

Publication number Publication date
EP0584208A1 (fr) 1994-03-02
PT100441A (pt) 1993-09-30
EP0584208A4 (fr) 1994-03-23
CA2102106A1 (fr) 1992-11-03
IE921376A1 (en) 1992-11-04
MX9202090A (es) 1992-11-01
JPH06507405A (ja) 1994-08-25
ZA923210B (en) 1993-03-31
CN1067244A (zh) 1992-12-23
AU1917092A (en) 1992-12-21

Similar Documents

Publication Publication Date Title
WO1992019594A1 (fr) Pyrrolidinones
JP3195352B2 (ja) アレルギーおよび炎症疾患の治療用化合物
EP0470805B1 (fr) Carbamates d'oxime et carbonates d'oxime comme bronchodilatateurs et anti-inflammatoires
JP3192424B2 (ja) アレルギーまたは炎症疾患の治療用化合物
IE913855A1 (en) Imidazolidinone compounds
EP0749417B1 (fr) Composes de cyano et leur preparations
US6300372B1 (en) 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates
JP3199380B2 (ja) 化合物
CZ283425B6 (cs) Fenylové deriváty a farmaceutické prostředky s jejich obsahem
WO1993007141A1 (fr) 3-phenylpyrrolidine-2-ones heterocycliques, leurs preparation et utilisation pour la fabrication d'un medicament permettant d'inhiber la production du facteur de necrose tumorale
WO1993015045A1 (fr) Derives d'acide n-(3-phenylpropyle) oxamique, d'oxamate et d'oxamide
WO1993015044A1 (fr) Derives d'acide n-benzyloxamique, d'oxamate et d'oxamide et leur utilisation comme inhibiteurs du facteur de necrose tumorale (fnt) et de la phosphodiesterase iv (pde iv)
EP0642489A1 (fr) Cyclopentane et derives de cyclopentane presentant une activite antiallergique, anti-inflammatoire et inhibant le facteur necrotique tumoral
JPH09503505A (ja) 化合物、組成物ならびにアレルギーおよび炎症の治療
US6013827A (en) Compounds
JPH11507331A (ja) ４，４−（二置換）シクロヘキサン−１−オール類モノマーおよび関連化合物
US5891883A (en) 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US5990119A (en) 1,4,4-(trisubstituted)cyclohexane monomers and related compounds
JP2873090B2 (ja) アレルギーおよび炎症疾患の治療用化合物
EP0794774B1 (fr) Monomeres de 4,4-(disubstitue)cyclohexan-1-oles et composes apparentes
US5767151A (en) 3,3-(disubstituted) cyclohexan-1-ylidine acetate dimers and related compounds
US5710180A (en) Phenethylamine compounds
US5900417A (en) 1,3,3-(Trisubstituted)cyclohexanemonomers and related compounds
US5777176A (en) 4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds
US5777160A (en) 1, 4, 4-(trisubstituted) cyclohex-1-ene dimers and related compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992911583

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1993 137170

Country of ref document: US

Date of ref document: 19931027

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2102106

Country of ref document: CA

EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWP Wipo information: published in national office

Ref document number: 1992911583

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1992911583

Country of ref document: EP